The FDA has so far secured 600 new hires and is looking for 1,600 more as interim leadership at the agency looks to rebuild the workforce and morale after more than a year of intense attrition.
FDA hiring 2,200 people to staff up after last year’s DOGE cuts Read More »
A new report from RBC Capital Markets lists Biotechnology Innovation Organization chief executive John Crowley and military physician Heidi Overton as potential candidates for the role of FDA commissioner—as is the agency’s current acting leader, top food regulator Kyle Diamantas.
BIO CEO Crowley, DOD doctor Overton are top candidates for FDA commissioner: RBC Read More »
A few short days after announcing an FDA pivot on a separate asset, REGENXBIO is planning to test the agency’s apparent newfound rare disease outlook on another late-stage gene therapy.
REGENXBIO bets on FDA flexibility with filing plans for Duchenne gene therapy Read More »
Lilly has already spent more than $25 billion in potential business development commitments this year, including the $6.3 billion buyout of Centessa Pharmaceuticals that closed today.
Lilly deepens relationship with China’s Abbisko for $1.9B biobucks Read More »
The combined business entity with Boundless Bio, which will carry Serapha Bio’s name and fold in Boundless Bio, will focus on the development of a gene editor for alpha-1 antitrypsin deficiency.
Serapha takes reverse merger route to Nasdaq with $230M and gene editor from China Read More »
AbbVie scooped up immunology player Apogee Therapeutics for nearly $11 billion in one of the year’s top deals to-date, while Sanofi made a big play to survive its upcoming Dupixent patent cliff; FDA uncertainty continues as the agency changes direction on gene therapies by uniQure and REGENXBIO; and Jef Akst and Annalee Armstrong report back
AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more Read More »
To avoid losing funding, many states are pursuing proven cost-saving models, such as downsizing inpatient care, rather than novel, untested approaches, some experts say.
The $50B rural health transformation fund is pushing many hospitals to shrink Read More »
Speaking to media on Tuesday, BIO CEO John Crowley complimented China’s rise as a biotech powerhouse but said U.S. policy needs to protect and maintain America’s lead.
BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech Read More »
For the 2026 fiscal year, Takeda anticipates declines in revenue and profit, highlighting what CEO-elect Julie Kim says is the need for the company to “invest in future growth.”
Takeda enters transitional year as new CEO seeks return to growth Read More »
With positive feedback on a Phase 3 trial design, Ollin Biosciences has collected a $330 million series B to advance its VEGF/Ang2 antibody, which bested Genentech’s therapy in a head-to-head study.
Ollin parlays Vabysmo beat into $330M raise to test eye disease drug in Phase 3 Read More »
